Join        Login             Stock Quote

VIVUS (VVUS) Shares Jump After Qsymia Study Results

 February 01, 2013 07:57 AM

(By Balachander) VIVUS Inc. (NASDAQ: VVUS) said a study concluded its weight-loss drug Qsymia significantly improved multiple cardiovascular disease risk factors, and its shares jumped 6.11 percent in premarket trading on Friday.

The biopharmaceutical company said patients with hypertension or high cholesterol treated with Qsymia for one year experienced significant weight loss and clinically meaningful improvements in their underlying cardiovascular risk factors.

Qsymia was approved by the U.S. Food and Drug Administration (FDA) in July 2012, with sales launched on September 17.

In the study, the company said, Qsymia produced significantly greater dose-related mean percentage weight loss compared with placebo in the subgroups of participants with dyslipidemia and those with hypertension.

[Related -Aetna Inc (AET) & Coventry Health Care, Inc. (CVH): Game Changer]

The improvements were significantly greater among patients who lost 10% or more of their starting weight, VIVUS said.

In the four-week period ended Oct. 26, Qsymia prescriptions shipped was 5,394, a regulatory filing showed.

Health insurer Aetna (NYSE: AET) had late last year decided to provide coverage for Qsymia.

Obesity is a chronic condition defined by having excess body fat. According to the World Health Organization and CDC, more than 500 million people worldwide and roughly one-third of American adults are obese.

[Related -Aetna Inc (AET): Fundamental Stock Research Analysis]

The stock, which has been trading in the 52-week between $9.86 and $31.21, closed at $12.11 on Thursday.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageThe S&P 500’s Worrisome Downturn In Drawdown

Last Friday I reviewed some of the bearish signals that were casting dark shadows across the US stock read on...

article imageADP: Private-Sector Employment Rises A Solid 200k In September

The pace of growth for private-sector employment picked up in September, according to this morning’s ADP read on...

article imageTreasury Market’s Inflation Expectations Tumble

The odds for a Fed rate hike are falling like a stone, or so it appears based on the implied inflation read on...

article imageEmerging Market Stocks: Last Week’s Red-Ink Leader

Value investors on the lookout for bargains have recently been eyeing up the battered corner of emerging read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.